Goal and Learning Outcomes

Upon completion of this activity, you should be better able to:

  • Review disease prevalence, pathophysiology, morbidity, and morality of SSc-ILD
  • Identify key risk factors and diagnostic tests to improve early symptom recognition and prognosis of SSc-ILD
  • Interpret key data on recently approved and emerging treatment options for SSc-ILD to improve clinical management
  • Describe best practices for effective communication and coordination between rheumatologists and pulmonologists to optimize patient outcomes


Elizabeth R. Volkmann, MD, MS

Director, UCLA Scleroderma Center
Co-Director UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles

Lisa H Lancaster, MD

Professor of Medicine
Director, Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, Tennessee

Accreditation Information

This course is being provided by a Relias LLC strategic partner.  Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.